Abstract
Objective
The effect of adalimumab on work productivity and occupational functioning was evaluated in patients with moderate to severe psoriasis during a prospective 24-week open-label, single-center trial.
Methods
Thirty-four patients received adalimumab 80 mg subcutaneously at week 0, followed by 40 mg every other week from weeks 1 through 24. Patients were allowed to continue previous topical treatments and phototherapy while enrolled. Occupational functioning was evaluated at monthly intervals throughout the study using the Work Productivity and Activity Impairment Questionnaire—Specific Health Problem.
Results
There was a statistically significant improvement from baseline to week 24 in the percent of impairment while working (P = 0.0029) and in the percent of overall work impairment (P = 0.0026). The percent of work time missed because of psoriasis decreased, but this change did not reach statistical significance (P = 0.11).
Conclusion
Adalimumab was efficacious in improving work and activity limitations in patients with moderate to severe psoriasis over a 24-week period.
Keywords
Get full access to this article
View all access options for this article.